Galmed Partners with Tel Aviv University to Test Brain Cancer Therapy Potential
Galmed Pharmaceuticals is partnering with Tel Aviv University to explore its drug Aramchol as a potential treatment for metastatic brain cancer.
Galmed Pharmaceuticals is partnering with Tel Aviv University to explore its drug Aramchol as a potential treatment for metastatic brain cancer.
Galmed Pharmaceuticals has developed a brain-penetrating Aramchol formulation using nanotech, showing promise for Parkinson's and dementia treatments.
Galmed Pharmaceuticals secures South Korea patent for innovative liver disease combination therapy, extending global protection.